Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
- 8 October 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Neurology
- Vol. 14 (11), 639-652
- https://doi.org/10.1038/s41582-018-0079-7
Abstract
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine — most notably, oncology and cardiovascular diseases — allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.Keywords
This publication has 129 references indexed in Scilit:
- From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicineEPMA Journal, 2013
- Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy seriesActa Neuropathologica, 2013
- Plasma tau levels in Alzheimer's diseaseAlzheimer's Research & Therapy, 2013
- Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's diseaseNature Reviews Drug Discovery, 2013
- Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problemsAlzheimer's Research & Therapy, 2013
- Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and interventionProgress in Neurobiology, 2011
- Incidence of Post-Dural Puncture Headache in Research VolunteersHeadache: The Journal of Head and Face Pain, 2011
- A map of human genome variation from population-scale sequencingNature, 2010
- Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and SerumCNS Neuroscience & Therapeutics, 2009
- Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health StudyNeurology, 2008